Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 15/20 | 0.59 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3763117 | 0.79 | ABL1 (0.67) | ABL1PIK3CAPIK3CG | |
| SCHEMBL3767021 | 0.79 | ABL1 (0.60) | ABL1PIK3CAPIK3CG | |
| SCHEMBL1282482 | 0.78 | ABL1 (0.68) | ABL1PIK3CAPIK3CGNPC1RAB9A | |
| SCHEMBL15260016 | 0.77 | ABL1 (0.59) | ABL1PIK3CAPIK3CGNPC1RAB9A | |
| SCHEMBL1685098 | 0.76 | ABL1 (0.65) | ABL1PIK3CAPIK3CGNPC1RAB9A | |
| SCHEMBL4496509 | 0.73 | NPC1 (0.69) | ABL1PIK3CAPIK3CGNPC1RAB9A | |
| SCHEMBL16975200 | 0.72 | ABL1 (0.43) | ABL1PIK3CAPIK3CGNPC1RAB9A | |
| SCHEMBL14824329 | 0.72 | NPC1 (0.64) | ABL1PIK3CAPIK3CGNPC1RAB9A | |
| SCHEMBL1282409 | 0.71 | ABL1 (0.49) | ABL1PIK3CAPIK3CG | |
| SCHEMBL1282435 | 0.71 | ABL1 (0.51) | ABL1PIK3CAPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3102203-A2 | ANTIBACTERIAL COMBINATIONS COMPRISING POLYMYXIN | SPERO GYRASE, INC. (US) | 2016-12-14 | — | — | EP | disclosed |
| WO-2015114452-A2 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LTD (GB) | 2015-08-06 | — | — | WO | disclosed |